US Stocks Movements | Rani Therapeutics (RANI.US) Soars Over 265% After $1.085 Billion Partnership Agreement with Chugai Pharmaceutical

Stock News
10/17

On Friday, Rani Therapeutics (RANI.US) surged over 265%, triggering a trading halt at one point and hitting a new annual high of $1.76. The spike in stock price follows the company’s announcement of a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The agreement includes a $10 million upfront payment, eligibility for up to $75 million in technology transfer and development milestone payments, $100 million in sales milestone payments, and a single-digit royalty. Additionally, Chugai has the option to expand the collaboration to five additional drug targets. Rani Therapeutics specializes in oral delivery technologies for biopharmaceuticals, with its core platform, RaniPill®, dedicated to the development of oral antibodies and treatments for rare diseases. This collaboration focuses on Chugai's rare disease antibody projects to validate the technological application value.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10